High-Yield LeukoCore™ Breast Cancer Leukopaks for Research

LeukoCore™ Breast Cancer Leukopak biospecimens are collected from donors clinically diagnosed with breast cancer through IRB-approved apheresis procedures. Each human leukopak contains large quantities of peripheral blood mononuclear cells (PBMCs), making it ideal for immunotherapy development, biomarker discovery, and examining genetic risk factors.

Product Features

• Research Use Only (RUO) human breast cancer leukopaks
• Clinically confirmed breast cancer donors
• High cell yield for large-scale studies
• Processed and shipped within 24 hours of collection
• Fresh or cryopreserved options available
• IRB-approved and ethically sourced
• Infectious disease testing
• HLA-A typing
• Screen donors with LeukoLot™

Donor Metadata

• Verified breast cancer diagnosis from healthcare providers
• Donor demographics: age, sex assigned at birth, race/ethnicity
• Self-reported medication history and allergies
• Relevant clinical data including breast cancer associated mutations (if available)

Applications

• Immune cell characterization in breast cancer
• Therapeutic development and screening
• Cell-based assays and cytokine profiling
• Multi-omics studies including single-cell sequencing

Compliance and Quality Assurance

• Collected under IRB oversight with donor e-consent (21 CFR Part 11 compliant)
• HIPAA-compliant handling of donor information
• Rigorous donor screening and documentation

Ordering & Customization

Breast Cancer Leukopak samples are available fresh or cryopreserved. For international shipping or regulatory documentation, please contact to confirm regional compliance and shipping availability.